5-MeO-DMT

5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine) is an extremely powerful psychedelic tryptamine. It differs from N,N-DMT by a very strong selectivity for the 5-HT1A receptor and by markedly lower active doses. It is present in the secretion of the toad Incilius alvarius (formerly Bufo alvarius) and in certain plants. In the psychedelic counterculture it is nicknamed The God Molecule, in reference to the phenomenology of non-dual unity and luminous void that it induces. The nickname is recent, and the history of the compound is more prosaic than its legend.

Pharmacology

5-MeO-DMT shows a very high affinity for the 5-HT1A receptor, with an inhibition constant on the order of 2 to 3 nM, a reported selectivity of 300 to 1000 fold over 5-HT2A, while retaining 5-HT2A agonist activity. It also acts at 5-HT2C, and at the σ1 and TAAR1 receptors.

It is this functional weight of 5-HT1A that gives 5-MeO its signature: it underlies dissolution, emptiness and a paradoxical anxiolysis. 5-HT2A provides the psychedelic component and the collapse of the self-model. The difference from N,N-DMT is not a mirror inversion of the two receptors, since N,N-DMT shows no clear dominance and is itself a 5-HT1A agonist; it lies in 5-MeO's selectivity and potency, which make it active where N,N-DMT is not yet.

As a substrate of MAO-A, the compound is rapidly broken down when swallowed, and vaporisation remains the reference route. Oral activity under an MAOI was documented from the early 1990s. What Jonathan Ott established in 2001 by self-experiment is different and more interesting: activity by the intranasal route without an MAOI, with a threshold around 10 mg of freebase, and clear potentiation by small amounts of harmine or harmaline. Shulgin, for his part, reports a 35 mg oral trial that produced no activity: both findings coexist in the literature.

Mechanisms

5-MeO-DMT causes a rapid collapse of the boundaries of the self, a disintegration of the default mode network (DMN) and a profound alteration of perceptual integration. 5-MeO tends less towards the production of content than towards the erasure of content.

One observes a marked decrease in DMN coherence, an increase in brain entropy, an alteration of self-models and of the subject / object separation, and a marked alpha suppression, with an EEG dynamics distinct from that of N,N-DMT. According to a phenomenological hypothesis, the cortical dissolution of the self may converge with intense interoceptive signals, reinforcing the impression of real death. The corresponding phenomenology overlaps with the territory identified as the deepest threshold of N,N-DMT, the collapse of the residual observer (see Mapping the thresholds under N,N-DMT).

Phenomenology

The experience is brief, often of extreme phenomenological intensity, with a bimodality of valence. It is characterised by a complete dissolution of the ego and a non-duality, the perception of a luminous void or of a limitless consciousness.

Two poles coexist: a luminous pole (peace, unconditional love, unity) and an annihilation pole (death experienced as real, possible ontological terror). Temporality is abolished or undecidable. In its prototypical form, a distinctive feature is the near-absence of complex visual content or of entities, in contrast to N,N-DMT (see the nuance below).

Typical subjective effects include an ego dissolution and a total loss of the sense of self, unity and a centreless consciousness, a profound peace, a bliss and an unconditional love, a void and a white light, an ineffability, an ego death experienced as real, all within a very brief but potentially overwhelming experience.

5-MeO-DMT occupies a singular place in the psychedelic repertoire: a phenomenology of erasure rather than of replacement, an extreme subjective intensity, and a risk profile of its own. It is not a stronger N,N-DMT, but a different molecule, with its own pharmacological and experiential profile. 5-MeO-DMT does not show more content: it tends towards less content, up to the void or total erasure. It is thus the prototypical molecule of a territory occasionally reached under high-dose N,N-DMT (see Breakthrough under N,N-DMT).

Beyond the prototypical opposition

5-MeO is readily summed up as a pure whiteness, a contentless ego death, by contrast with the entities of N,N-DMT. That description targets a prototypical pole, an idealised limit, more than an invariant of every session.

Testimonies in fact describe a range: a luminous form, waves of love or relational warmth, geometric or near-figurative content, re-entry visions, especially on the come-up, on the way down, or below the full-release threshold. The total white-out is the limit-case, not the rule. The bimodality of valence (luminous union or annihilation terror) already shows that this is not a flat, uniform nothingness, and the boundary with the N,N-DMT territory is porous (the convergence at the deepest threshold, noted above, runs both ways).

The ego death of 5-MeO is above all of a different nature from that of N,N-DMT: an erasure toward a centreless field (monadic ownerlessness) rather than a relational dissolution by co-emergence. To oppose void and entities here is to mistake two forms of self-dissolution for dissolution versus non-dissolution. For integration, expecting only the void can lead one to miss, or to mishandle, the dimensions of form and relation that also arise.

Duration and tolerance

Vaporised or smoked, the effect begins within 20 to 60 seconds, peaks within 1 to 3 minutes, has a plateau of 5 to 15 minutes, then a return within 30 to 120 minutes. A phase of immobility at the peak is frequent (2 to 5 minutes). Swallowed, breakdown by MAO-A leaves quantities equivalent to vaporised doses inactive.

Acute tolerance is relatively low, and closely spaced doses are sometimes still active. It is recommended to space sessions widely apart.

Harm reduction

The documented physiological risk of 5-MeO-DMT is not the one usually attributed to it. Serotonin toxicity from combination with an MAOI is established, and the index case says everything about where it came from: monoamine oxidase inhibitor poisoning resulting from internet misinformation, a 17-year-old in December 2002, Syrian rue followed by smoked 5-MeO-DMT, seizures and 41.1 °C. The second real risk is loss of motor control: unconsciousness or unresponsiveness lasting one to ten minutes is frequent above 8 to 10 mg smoked, and the concretely documented fatal mechanism is asphyxia from vomiting during that window. Against this, a phase 1 trial of 2 to 18 mg vaporised altered neither blood pressure nor heart rate and produced no serious adverse event: a cardiotoxicity intrinsic to the molecule is not established, and the only published pharmacological death was contested by a group including Shulgin, Nichols, Grob, Dennis McKenna, Callaway and Tupper.

The main remaining risks are psychological, which is exactly what the warnings of 1998 to 2002 said before they became inaudible: PTSD-type reactions lasting days, weeks, months or years, two reported cases of severe persistent anxiety disorders after strong doses, and the fact that groups practising pharmahuasca reported a far higher incidence of bad reactions with 5-MeO than with N,N-DMT, to the point of dropping it. Sober supervision is required: never use it alone. Contraindications include uncontrolled cardiovascular disease and a history of psychosis. The general principles apply here with the margin for error reduced to nothing (see Harm reduction).

Harvesting from Incilius alvarius raises the issue of a vulnerable species and a contested trade. The IUCN Least Concern status rests on a 2004 assessment; the species is listed as Threatened in New Mexico, presumed extirpated from California, and taking ten toads a year remains legal in Arizona with a fishing licence, with no population monitoring able to say whether collection is sustainable. Synthetic production is preferable, for controlled purity as much as for the animal. Ken Nelson, the man who made the venom known, himself favoured a synthetic supply; the route actually published is not his but Hamilton Morris's, released with his agreement.

5-MeO-DMT also occurs in certain plants, but not the ones usually named: analyses of Psychotria viridis and Mimosa tenuiflora find only N,N-DMT. The real botanical sources are the Virola bark-resin snuffs, where it is the major alkaloid, the bark of Anadenanthera peregrina, and grasses of the genus Phalaris.

Three lineages, one legend

The compound is now almost synonymous with the toad. That equivalence flattens three distinct lineages, two of which predate the toad entirely.

The oldest is botanical. 5-MeO-DMT was first isolated from a natural source in 1959, from Dictyoloma incanescens; its presence in Anadenanthera peregrina was established only in 1963, and in the bark, not the seeds. Two ethnobotanical lineages must be kept carefully apart: yopo, cohoba and cebil, made from Anadenanthera, where the dominant alkaloid is bufotenine and 5-MeO-DMT remains very minor, and epená and nyakwana, prepared from Virola bark resin, where 5-MeO-DMT genuinely is the principal constituent.

The second lineage is chemical, and it is the one that actually supplied the first Western users. Synthesised in 1936 by Hoshino and Shimodaira, the compound remained federally unscheduled in the United States until 19 January 2011. In 1971 John Mann incorporated the Church of the Tree of Life in California, whose doctrine deserves to be read exactly: it could not claim as sacraments any substance made illegal before its own incorporation, other churches having failed in the attempt, and so proclaimed as sacrament everything that was not yet illegal. The dividing line is chronological and legal, not pharmacological or moral, and the book in fact describes peyote in detail while excluding it from sacramental status. 5-MeO-DMT fell under that general definition, but it is named nowhere in the First Book of Sacraments of August 1972, whose sixteen sacraments are all plants. According to the Erowid chronology, the sole source for this, it was distributed to members by the Inner Center entity from about 1971 to the late 1980s, laid on parsley. The same source gives over 6000 members in 1979. Choosing a molecule because it escapes the nomenclature rather than because it belongs to a tradition is already the conceptual matrix of research chemicals, and the descent is direct: Adam Gottlieb's manual Legal Highs, in 1973, cites the church and already sets out how to order unscheduled compounds from chemical suppliers.

The third lineage is the toad, and it is the most recent. In 1981 a note in Omni magazine about exhumed toad bones put Ken Nelson on a trail; the note was in fact about bufotenine and about a Cherokee ceremonial site in South Carolina, unrelated to the Sonoran Desert, and it was Nelson who made the connection by reading Erspamer. That work had established, in a preliminary note in 1965 and then a full paper in 1967, that the parotoid and coxal glands of Incilius alvarius concentrate 5-MeO-DMT to a degree the authors called unique among the forty or so Bufo species examined in their laboratory. In 1983, after one failed expedition, Nelson collected venom in the Sonoran desert, dried it and smoked it. In 1984, under the pen name Albert Most, he self-published with Venom Press a pamphlet illustrated by Gail Patterson, which circulated as a photocopy. He was not bringing a new molecule: he was bringing a biological source and a story.

The pamphlet carried no warning at all. It describes colours more beautiful than usual, visual hallucinations and fits of laughter, states that there is neither hangover nor harmful effect, and ends with Enjoy your trip. It puts the psychoactive dose at 3 to 5 mg, where the scholarly literature of the same decade places it between 6 and 20 mg: a factor of two to three, on a molecule where unconsciousness begins around 8 to 10 mg.

What TIHKAL actually reports

The 5-MeO-DMT entry in TIHKAL, in 1997, is often reduced to a reservation on Shulgin's part. His personal comment there is in fact technical and neutral, and his comparative table of 5-methoxylated tryptamines places the compound among those marked positive, psychedelic, out-of-body, at 6 to 20 mg. What the chapter mainly shows is that variety is the fact, not convergence.

The thirteen accounts range from two words, no activity, to reports of three hundred. At 6 mg, one witness describes a merely stunning drug, with no sensory or intellectual input. At 10 mg, no notable visual effects, everything over within an hour, and this sentence: all of my blood had turned to concrete. At 15 mg, an extremely fine multicoloured phosphene filling the visual field for one, and for another a merciless and horrible love that frightened him badly. At 30 mg, foetal position and terror of dying. At 35 mg orally, no activity. And at an unknown strong dose, the only sequence in the whole book where a resuscitation is described, with two respiratory arrests, cardiac massage, then medical intervention three days later: it is in this chapter.

It is also here, in an anonymous account of a 25 mg dose, that the word white-out is coined, explicitly by contrast with black-out, by a witness who notes that he retains almost no memory of the state, not even whether his eyes were open or closed. The original sense was therefore amnesic and descriptive, not theological.

One frequent confusion should be cleared up: the reports of chest pressure attributed to 5-MeO-DMT in fact belong to the entry on bufotenine, and come from intravenous injections given in the 1950s to psychiatric patients and prisoners, trials Shulgin cites precisely in order to condemn their ethics. The body load and the buzzing, by contrast, are well attested for 5-MeO-DMT.

The making of a story

The God molecule nickname, which calques Strassman's Spirit Molecule, rests on a retrospective self-attribution: Martin Ball states that he gave it in 2008, but no document using the phrase between 2008 and 2015 could be produced. The term enters the printed book trade in 2016, with two titles published the same year by the same small Californian press, in a milieu where the authors preface and publish one another.

The ancestry is later still than the nickname. A Comcaac community in Sonora set up a foundation around the toad in 2011, the practice being introduced to address methamphetamine use among young people; the academic literature of 2026 concludes that there is no ethnographic record of ceremonial consumption of the secretion before that date, and the Yaqui have stated that accounts of historical cultural use are fabricated. The hypothesis of Mesoamerican ritual toad use is moreover often wrongly attributed to Weil and Davis: in their 1992 and 1994 papers those authors reject the hypothesis concerning Bufo marinus, judged too toxic, and propose Incilius alvarius as a replacement candidate, in the conditional. Nothing has substantiated it since, neither in the codices nor by material evidence, and the species is not in any case Mesoamerican.

The venom itself has been measured: about 41 percent 5-MeO-DMT against 0.28 percent bufotenine in the dried secretion, which leaves the entourage-effect argument without a basis. And the widespread claim that it is powerful enough to kill a full-grown dog is contradicted by the only published clinical series: of 208 intoxicated dogs presented to Arizona veterinary emergency services, 206 left alive.

Sources

• Hoshino and Shimodaira (1936), synthesis of the compound; primacy is disputed, but the 1935 date sometimes cited refers to work on bufotenine alone
• Pachter, Zacharias and Ribeiro (1959), first isolation from a natural source, Dictyoloma incanescens
• Legler and Tschesche (1963), isolation from the bark of Anadenanthera (Piptadenia) peregrina
• Erspamer et al. (1965), preliminary note, and Erspamer et al. (1967), full paper establishing the content of the parotoid and coxal glands
• Efron, Holmstedt and Kline (eds), Ethnopharmacologic Search for Psychoactive Drugs (1967), analysis of South American snuffs and the MAOI hypothesis
• Alexander and Ann Shulgin, TIHKAL: The Continuation (1997), entry #38; entry #19, on bufotenine, contains the 1950s intravenous injection reports
• Ott (2001), human intranasal, sublingual and oral pharmacology, and potentiation by beta-carbolines
• Weil and Davis (1992) and Weil and Davis (1994), where pre-Columbian toad use is proposed in the conditional after rejection of the Bufo marinus hypothesis
• Brush, Bird and Boyer (2004), MAOI poisoning following misinformation found online
• Reckweg et al. (2021), phase 1 trial, 2 to 18 mg vaporised, cardiovascular tolerability
• Schwelm et al. (2022), quantitative composition of harvested venom
• Ortiz Bernal et al. (2026), fabricated ancestrality, the ecological politics of 5-MeO-DMT
• DEA, Federal Register (2010), federal Schedule I placement, effective 19 January 2011
• The First Book of Sacraments of the Church of the Tree of Life, Tree of Life Press, San Francisco, August 1972
• Albert Most [Ken Nelson], Bufo alvarius: The Psychedelic Toad of the Sonoran Desert, Venom Press, 1984, illustrations by Gail Patterson
• Adam Gottlieb, Legal Highs, 20th Century Alchemist, 1973
• James Oroc, Tryptamine Palace: 5-MeO-DMT and the Sonoran Desert Toad, Park Street Press, 2009
• Jonathan Ott, Pharmacotheon: Entheogenic Drugs, Their Plant Sources and History, Natural Products Co., 1993
• Erowid, 5-MeO-DMT timeline, Health and Fatalities pages, and the Sonoran Desert Toad site archives